A Network Pharmacology-Based Study on the Anti-Lung Cancer Effect of Dipsaci Radix

Objective. Dipsaci Radix (DR) has been used to treat fracture and osteoporosis. Recent reports have shown that myeloid cells from bone marrow can promote the proliferation of lung cancer. However, the action and mechanism of DR has not been well defined in lung cancer. The aim of the present study w...

Full description

Bibliographic Details
Main Authors: Jiayan Wu, Shengkun Hong, Xiankuan Xie, Wangmi Liu
Format: Article
Language:English
Published: Hindawi Limited 2020-01-01
Series:Evidence-Based Complementary and Alternative Medicine
Online Access:http://dx.doi.org/10.1155/2020/7424061
id doaj-baec6758109446dab256a194e0ad0b92
record_format Article
spelling doaj-baec6758109446dab256a194e0ad0b922020-11-25T02:25:24ZengHindawi LimitedEvidence-Based Complementary and Alternative Medicine1741-427X1741-42882020-01-01202010.1155/2020/74240617424061A Network Pharmacology-Based Study on the Anti-Lung Cancer Effect of Dipsaci RadixJiayan Wu0Shengkun Hong1Xiankuan Xie2Wangmi Liu3Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200032, ChinaQuzhou People’s Hospital, No. 2 Zhongloudi, Quzhou 324000, ChinaThe Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310009, ChinaThe Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310009, ChinaObjective. Dipsaci Radix (DR) has been used to treat fracture and osteoporosis. Recent reports have shown that myeloid cells from bone marrow can promote the proliferation of lung cancer. However, the action and mechanism of DR has not been well defined in lung cancer. The aim of the present study was to define molecular mechanisms of DR as a potential therapeutic approach to treat lung cancer. Methods. Active compounds of DR with oral bioavailability ≥30% and drug-likeness index ≥0.18 were obtained from the traditional Chinese medicine systems pharmacology database and analysis platform. The potential target genes of the active compounds and bone were identified by PharmMapper and GeneCards, respectively. The compound-target network and protein-protein interaction network were built by Cytoscape software and Search Tool for the Retrieval of Interacting Genes webserver, respectively. GO analysis and pathway enrichment analysis were performed using R software. Results. Our study demonstrated that DR had 6 active compounds, including gentisin, sitosterol, Sylvestroside III, 3,5-Di-O-caffeoylquinic acid, cauloside A, and japonine. There were 254 target genes related to these active compounds as well as to bone. SRC, AKT1, and GRB2 were the top 3 hub genes. Metabolisms and signaling pathways associated with these hub genes were significantly enriched. Conclusions. This study indicated that DR could exhibit the anti-lung cancer effect by affecting multiple targets and multiple pathways. It reflects the traditional Chinese medicine characterized by multicomponents and multitargets. DR could be considered as a candidate for clinical anticancer therapy by regulating bone physiological functions.http://dx.doi.org/10.1155/2020/7424061
collection DOAJ
language English
format Article
sources DOAJ
author Jiayan Wu
Shengkun Hong
Xiankuan Xie
Wangmi Liu
spellingShingle Jiayan Wu
Shengkun Hong
Xiankuan Xie
Wangmi Liu
A Network Pharmacology-Based Study on the Anti-Lung Cancer Effect of Dipsaci Radix
Evidence-Based Complementary and Alternative Medicine
author_facet Jiayan Wu
Shengkun Hong
Xiankuan Xie
Wangmi Liu
author_sort Jiayan Wu
title A Network Pharmacology-Based Study on the Anti-Lung Cancer Effect of Dipsaci Radix
title_short A Network Pharmacology-Based Study on the Anti-Lung Cancer Effect of Dipsaci Radix
title_full A Network Pharmacology-Based Study on the Anti-Lung Cancer Effect of Dipsaci Radix
title_fullStr A Network Pharmacology-Based Study on the Anti-Lung Cancer Effect of Dipsaci Radix
title_full_unstemmed A Network Pharmacology-Based Study on the Anti-Lung Cancer Effect of Dipsaci Radix
title_sort network pharmacology-based study on the anti-lung cancer effect of dipsaci radix
publisher Hindawi Limited
series Evidence-Based Complementary and Alternative Medicine
issn 1741-427X
1741-4288
publishDate 2020-01-01
description Objective. Dipsaci Radix (DR) has been used to treat fracture and osteoporosis. Recent reports have shown that myeloid cells from bone marrow can promote the proliferation of lung cancer. However, the action and mechanism of DR has not been well defined in lung cancer. The aim of the present study was to define molecular mechanisms of DR as a potential therapeutic approach to treat lung cancer. Methods. Active compounds of DR with oral bioavailability ≥30% and drug-likeness index ≥0.18 were obtained from the traditional Chinese medicine systems pharmacology database and analysis platform. The potential target genes of the active compounds and bone were identified by PharmMapper and GeneCards, respectively. The compound-target network and protein-protein interaction network were built by Cytoscape software and Search Tool for the Retrieval of Interacting Genes webserver, respectively. GO analysis and pathway enrichment analysis were performed using R software. Results. Our study demonstrated that DR had 6 active compounds, including gentisin, sitosterol, Sylvestroside III, 3,5-Di-O-caffeoylquinic acid, cauloside A, and japonine. There were 254 target genes related to these active compounds as well as to bone. SRC, AKT1, and GRB2 were the top 3 hub genes. Metabolisms and signaling pathways associated with these hub genes were significantly enriched. Conclusions. This study indicated that DR could exhibit the anti-lung cancer effect by affecting multiple targets and multiple pathways. It reflects the traditional Chinese medicine characterized by multicomponents and multitargets. DR could be considered as a candidate for clinical anticancer therapy by regulating bone physiological functions.
url http://dx.doi.org/10.1155/2020/7424061
work_keys_str_mv AT jiayanwu anetworkpharmacologybasedstudyontheantilungcancereffectofdipsaciradix
AT shengkunhong anetworkpharmacologybasedstudyontheantilungcancereffectofdipsaciradix
AT xiankuanxie anetworkpharmacologybasedstudyontheantilungcancereffectofdipsaciradix
AT wangmiliu anetworkpharmacologybasedstudyontheantilungcancereffectofdipsaciradix
AT jiayanwu networkpharmacologybasedstudyontheantilungcancereffectofdipsaciradix
AT shengkunhong networkpharmacologybasedstudyontheantilungcancereffectofdipsaciradix
AT xiankuanxie networkpharmacologybasedstudyontheantilungcancereffectofdipsaciradix
AT wangmiliu networkpharmacologybasedstudyontheantilungcancereffectofdipsaciradix
_version_ 1715490640862642176